Omar Abdel-Rahman1, Mona Fouad. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND: In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs). METHODS: Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response. RESULTS: In total, 16 trials including 348 patients were included. Median progression-free survival ranged from 6 to 31 months. The disease control rate ranged from 65 to 100%. Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases. CONCLUSION: The published clinical data suggest that TMZ-based combination with some anticancer agents (especially capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.
BACKGROUND: In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs). METHODS: Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response. RESULTS: In total, 16 trials including 348 patients were included. Median progression-free survival ranged from 6 to 31 months. The disease control rate ranged from 65 to 100%. Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases. CONCLUSION: The published clinical data suggest that TMZ-based combination with some anticancer agents (especially capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.
Authors: Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe Journal: Ann Surg Oncol Date: 2017-05-30 Impact factor: 5.344
Authors: Dwight H Owen; Andrew J Alexander; Bhavana Konda; Lai Wei; Jessica A Hemminger; Carl R Schmidt; Sherif R Z Abdel-Misih; Mary E Dillhoff; Jennifer A Sipos; Lawrence S Kirschner; Manisha H Shah Journal: Oncotarget Date: 2017-10-24